ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins

Nature Genetics

Volumn 19, Issue 2, 1998, Pages 175-178

  Waterman, Matthew J F ^a,b   Stavridi, Elena S ^a   Waterman, Jennifer L F ^a   Halazonetis, Thanos D ^a,b  

^a WISTAR INSTITUTE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; DEPHOSPHORYLATION; GENE EXPRESSION REGULATION; GENOTOXICITY; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN PHOSPHORYLATION; TUMOR SUPPRESSOR GENE;

ATAXIA; ATAXIA TELANGIECTASIA;

EID: 0031840253     PISSN: 10614036     EISSN: None     Source Type: Journal    
DOI: 10.1038/542     Document Type: Article

References (30)

1. Levine, A.J. p53, the cellular gatekeeper for growth and division. Cell 88, 323-331 (1997).
2. Kastan, M.B., Onyekwere. O., Sidransky, D., Vogelstein, B. & Craig. R.W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51, 6304-6311 (1991).
3. Kuerbitz, S.J., Plunkett B.S., Walsh, W.V. & Kastan, M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89, 7491-7495 (1992).
4. Clarke, A.R. et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362, 849-852 (1993).
5. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993).
6. Maltzman, W. & Czyzyk, L. UV irradiation stimulates levels of p53 cellular tumour antigen in nontransformed mouse cells. Mol. Cell. Biol. 4, 1689-1694 (1984).
7. Lowe, S.W. et at. p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-610 (1994).
8. Fisher, D.E. Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539-542 (1994).
9. Chernov, M. & Stark, G.R. The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. Oncogens 14, 2503-2510 (1997).
10. Haapajarvi, T., Pitkanen, K., Tsubari, M. & Laiho, M. p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. Mol. Cell. Biol. 17, 3074-3080 (1997).
11. Hupp, T.R., Meek, D.W., Midgley, C.A. & Lane D.P. Regulation of the specific DNA binding function of p53. Cell 71, 875-886 (1992).
12. Halazonetis, T.D., Davis, U. & Kandil, A.N. Wild-type p53 adopts a "mutan"-like conformation when bound to DNA. EMBO J. 12, 1021-1028 (1993).
13. Waterman, J.L.F., Shenk, J.L. & Halazonetis, T.D. The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. EMBO J. 14, 512-519 (1995).
14. Kastan, M.B. et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71, 587-597 (1992).
15. Khanna, K.K. & Lavin, M.F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. Oncogene 8, 3307-3312 (1993).
16. Liu, Z.G. et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 384, 273-276 (1996).
17. Savitsky, K. et al. A single Ataxia Telangiectasia gene with a product similar to PI3 kinase. Science 268. 1749-1753 (1995).
18. Shieh, S.Y., Ikeda, M., Taya, Y. & Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by Mdm2. Cell 91, 325-334 (1997).
19. Siliciano, J.D. et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev. 11, 3471-3481 (1997).
20. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997).
21. Kubbutat, M.H.G., Jones, S.N. & Vousden, K.H. Regulation of p53 stability by mdm2. Nature 387, 299-303 (1997).
22. Delphin, C. & Baudier, J. The protein kinase C activator, phorbol ester, cooperates with the wild-type p53 species of ras-transformed embryo fibroblasts growth arrest. J. Biol. Chem. 269, 29579-29587 (1994).
23. Soussi, T. & May, P. Structural aspects of the p53 protein in relation to gene evolution: a second look. J. Mol. Biol. 260, 623-637 (1996).
24. Aitken, A. 14-3-3 and its possible role in co-ordinating multiple signalling pathways. Trends Cell Biol. 6, 341-347 (1996).
25. Yaffe, M.B. et al. The structural basis for 14-3-3: phosphopeptide binding specificity. Cell 91, 961-971 (1997).
26. Muslin, A.J., Tanner, J.W., Allen, P.M. & Shaw, A.S. Interaction of 14-3-3 with signaling proteins is mediated by the recognition of phosphoserine. Cell 84, 889-897 (1996).
27. Hermeking, H. et al. 14-3-3σ is a p53-regulated inhibitor of G2/M progression. Mol. Cell 1, 3-11 (1997).
28. Ford, J.C. et al. 14-3-3 protein homologs required for the DNA damage checkpoint in fission yeast. Science 265, 533-535 (1994).
29. Peng, CY. et al. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of cdc25c on serine-216. Science 277, 1501-1505 (1997).
30. Waterman, M.J.F., Waterman, J.L.F. & Halazonetis, T.D. An engineered fours-tranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumour-derived p53 mutants. Cancer Res. 56, 158-163 (1996).